CABOMETYX (cabozantinib) for Renal Cell Carcinoma

Slideshow

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

This slideshow reviews drug information for CABOMETYX (cabozantinib), indicated for renal cell carcinoma.

Table of Contents

Slide 3: Indication, Dosage, and Administration
Slide 10: Use in Specific Populations
Slide 13: Clinical Pharmacology
Slide 18: Warnings and Precautions
Slide 23: Clinical Safety and Efficacy
Slide 32: Drug Storage and Supply
Slide 35: References

Next hm-slideshow in Renal Cell Carcinoma